Sharon Tamir has been the Co-Chair of the Program Committee for ASENT - American Society for Experimental Neurotherapeutics, since 2019. In 2020 she was invited to join the Board of ASENT as well as serve as a Board member.
Ms. Tamir is the Executive Director, Head of Neuro-Oncology and Infectious Diseases at Karyopharm Therapeutics and heads up the development of Selinexor (KPT330), which encompasses discovery and development of novel treatments for Glioblastoma and other neuro-oncology indications and infectious diseases. Over the years she has been overseeing the therapeutic progression through the preclinical studies necessary for pre-IND and IND filing, in addition to the protocol development and oversight of clinical studies.
Previously, Ms. Tamir was Sr. Director Head of Strategic Alliances at United Neuroscience, a role in which she served as the primary point of contact for building and maintaining collaborative and compliant long-term partnerships with key patient advocacy organizations, rare disease organizations, private foundations, and policymakers supporting UNS’s target diseases. Prior to that, Ms. Tamir led the neurodegenerative and infectious diseases programs at Karyopharm for 7 years.